WEST DRAYTON, England--(BUSINESS WIRE)--The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON® (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. Both Ferring and members of the healthcare community are disappointed that the recommended use is so restrictive.
Help employers find you! Check out all the jobs and post your resume.
